Results 251 to 260 of about 93,200 (346)

Successful Screening of Undiagnosed Psoriatic Arthritis in Primary Care Utilising Digital Interventions Within a Quality Improvement Programme [PDF]

Antoni Chan, Matthew Pearce, Liz Van Rossen   +2 more
openalex   +1 more source

The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed, Tasfiah Tasnim Maha, Sanjana Nowsher, Wasima Taslim, Fatema‐Tuz‐Zohora, Sabrina Sharmin, Hasina Yasmin   +6 more
wiley   +1 more source

Validation of Turkish psoriatic arthritis screening tool for psoriatic arthritis: A cross-sectional comparative study. [PDF]

Medicine (Baltimore)
Başar Kilic Ş, Kulu H, Salman H, Bektaş M.   +3 more
europepmc   +1 more source

T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets

Aging Cell, Volume 25, Issue 5, May 2026.
Immunosenescent T cells promote inflammatory skin diseases such as psoriasis, atopic dermatitis, rosacea, and seborrheic dermatitis via hyperactive signaling networks and SASP secretion. Consequently, intercepting downstream SASP, inhibiting internal pathways, or utilizing senolytics represents promising therapeutic interventions.
Conghui Liu, Ming Yang, Fugang Xiao, Jinrong Zeng   +3 more
wiley   +1 more source

Budget Impact of Secukinumab in Psoriatic Arthritis Patients with Contraindication to TNF-Alpha Inhibitors. [PDF]

Clinicoecon Outcomes Res
Permsuwan U, Dilokthornsakul P, Sawangjit R.   +2 more
europepmc   +1 more source

Death anxiety predicts fear of progression in people with rheumatic conditions

British Journal of Health Psychology, Volume 31, Issue 2, May 2026.
Abstract Background Rheumatic diseases often have a progressive course and place individuals at increased risk of mortality. Despite this, little research has investigated the relationship between death anxiety and fears about disease progression (FoP), and how these might relate to health‐related quality of life (HRQoL) outcomes.
Bethany Richmond, Louise Sharpe, Jack B. Boyse, Joanne Shaw, Rachel E. Menzies   +4 more
wiley   +1 more source

Excess cardiovascular morbidity in psoriatic arthritis and cardioprotective effects of biologic dmards: a propensity-matched analysis. [PDF]

Sci Rep
Tyczyńska K, Krajewski PK, Złotowska A, Szepietowski JC, Świerkot J.   +4 more
europepmc   +1 more source

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy.
Shan Pan, Teresa Tsakok, Ruoheng Wei, Nick Dand, Floris C. Loeff, Karien Bloem, Annick de Vries, David Baudry, Michael Duckworth, Angela Pushpa‐Rajah, Alice Russell, Ali Alsharqi, Gabrielle Becher, Ruth Murphy, Shyamal Wahie, Andrew Wright, Christopher E. M. Griffiths, Nick J. Reynolds, Jonathan Barker, Richard B. Warren, A. David Burden, Theo Rispens, Satveer K. Mahil, Joseph F. Standing, Catherine H. Smith, on behalf of the BADBIR Study Group, the BSTOP Study Group and the PSORT Consortium, Marilyn Benham, Sagair Hussain, Brian Kirby, Linda Lawson, Kathleen McElhone, Anthony Ormerod, Caroline Owen, Michael R. Barnes, Paola Di Meglio, Richard Emsley, Andrea Evans, Katherine Payne   +38 more
wiley   +1 more source

Assessing data quality of rheumatoid and psoriatic arthritis patients in the <i>All of Us</i> Research Program. [PDF]

JAMIA Open
Spotnitz M, Giannini J, Clark E, Ostchega Y, Litwin TR, Berman L.   +5 more
europepmc   +1 more source

Super‐Response to Guselkumab Treatment in Patients With Moderate‐to‐Severe Psoriasis: Real‐World Data With Up to Five Years of Follow‐Up in The Czech Republic

International Journal of Dermatology, Volume 65, Issue 5, Page 980-990, May 2026.
Super‐response to Guselkumab. ABSTRACT Background Guselkumab, a selective interleukin (IL)‐23 inhibitor, is approved for the treatment of moderate‐to‐severe plaque psoriasis. While randomized clinical trials have introduced the concept of “super‐responders” (SRe)—patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 ...
Martina Kojanova, Daniela Pejrilova, Jorga Fialova, Petra Cetkovska, Spyridon Gkalpakiotis, Alena Machovcova, Petr Arenberger, Jiri Stork, Tomas Dolezal, Martin Tichy, the BIOREP study group, Zdenek Antal, Monika Balaz, Jirina Bartonova, Gabriela Behrami, Linda Blahova, Petr Bohac, Martin Cetkovsky, Dominika Diamantova, Magdalena Dobiasova, Olga Filipovska, Jana Foldesova, Martina Grycova, Eduard Hrnciř, Jiri Horazdovsky, Katerina Hrazdirova, Monika Hudymacova, Marie Jandova, Hana Janatova, Lucie Jaresova, Ludmila Kajtmanova, Frantisek Keznikl, Peter Kicko, Zuzana Kondasova, Sarka Kozojedova, Jiri Korda, Jana Kreisslova, Anezka Kreisslova, Silvie Krchova, Lenka Kulmanova, Natalie Kunesova, Zdenka Kysilka, Iva Lomicova, Romana Machackova, Barbora Machackova, Lukas Mericko, Miroslav Necas, Helena Nemcova, Radka Neumannova, Michaela Novakova, Jitka Osmerova, Veronika Pallova, Veronika Patavova, Lucie Petrů, Marie Policarova, Tomas Pospisil, Simona Risianova, Filip Rob, Marcela Rozkosova, Libuse Sazmova, Jaroslav Sevcik, Iva Schmidtmayerova, Martin Sicha, Kristyna Sokolova, Eliska Stankova, Jan Sternbersky, Ivana Strouhalova, David Stuchlik, Alena Stumpfova, Katerina Svarcova, Katerina Tepla, Hana Tomkova, Jana Tresnak Hercogova, Simona Vachatova, Yvetta Vantuchova, Ivana Vejrova, Iva Zampachova   +76 more
wiley   +1 more source